Merck.com - Research and Development News 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.Merck Receives Breakthrough Therapy Designation for MK-5172/MK-8742, an Investigational Oral Combination Regimen for the Treatment of Chronic Hepatitis C Virus (HCV) Infection
Dateline City:
WHITEHOUSE STATION, N.J.
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
announced today that the U.S. Food and Drug Administration (FDA) has
granted MK-5172/MK-8742 Breakthrough Therapy designation for treatment
of chronic hepatitis C virus infection. MK-5172/MK-8742 is an all-oral
combination regimen consisting of MK-5172, an investigational HCV NS3/4A
protease inhibitor, and MK-8742, an investigational HCV NS5A replication
complex inhibitor.
...
Source: Merck.com - Research and Development News - October 22, 2013 Category: Pharmaceuticals Tags: Research and Development News Corporate News Latest News Source Type: news
Results of Phase II PRECEDENT Trial for Investigational Folate Receptor Therapy Vintafolide in Patients with Platinum-Resistant Ovarian Cancer Published in Journal of Clinical Oncology
Dateline City:
WHITEHOUSE STATION N.J., & WEST LAFAYETTE, Ind.
Merck and Endocyte’s Phase III PROCEED pivotal trial of vintafolide in ovarian cancer ongoing
WHITEHOUSE STATION N.J., & WEST LAFAYETTE, Ind.--(BUSINESS WIRE)--Merck, known as MSD outside the United States and Canada, (NYSE: MRK)
and Endocyte, Inc. (NASDAQ: ECYT) today announced the online publication
of results from the randomized Phase II PRECEDENT trial for vintafolide
(MK-8109/EC145), an investigational ...
Source: Merck.com - Research and Development News - October 14, 2013 Category: Pharmaceuticals Tags: Research and Development News Corporate News Latest News Source Type: news
Interim Data for Merck’s MK-3475, an Investigational Anti-PD-1 Immunotherapy, in Previously Treated Patients with Non-Small Cell Lung Cancer to be Presented at 15th World Conference on Lung Cancer
Dateline City:
WHITEHOUSE STATION, N.J.
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
confirmed today that interim data from the company’s Phase IB expansion
study (PN 001) evaluating the efficacy and safety of *MK-3475 in
patients with refractory non-small cell lung cancer (NSCLC) is scheduled
for presentation at the 15th
World Conference on Lung Cancer on Oct. 29 at 4:15 p.m., (1:15 a.m.
EDT), in Sydney, Australia.
Language:
...
Source: Merck.com - Research and Development News - October 1, 2013 Category: Pharmaceuticals Tags: Research and Development News Corporate News Latest News Source Type: news
Data from Merck’s Investigational Hepatitis C Treatment Portfolio to be Presented at the 64th American Association for the Study of Liver Diseases Annual Meeting
Dateline City:
WHITEHOUSE STATION, N.J.
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced the presentation of data from studies evaluating the
company’s investigational oral chronic hepatitis C virus (HCV)
treatments MK-5172 and MK-8742 at the 64th American
Association for the Study of Liver Diseases Annual Meeting (AASLD). The
meeting is scheduled to take place in Washington, D.C., Nov. 1-5, 2013.
Language:
...
Source: Merck.com - Research and Development News - October 1, 2013 Category: Pharmaceuticals Tags: Research and Development News Corporate News Latest News Source Type: news
Merck Receives Complete Response Letter for Investigational Medicine Sugammadex Sodium Injection
Dateline City:
WHITEHOUSE STATION, N.J.
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
announced today that the company has received a Complete Response Letter
from the U.S. Food and Drug Administration (FDA) for the resubmission of
the New Drug Application for sugammadex sodium injection, Merck’s
investigational medicine for the reversal of neuromuscular blockade
induced by rocuronium or vecuronium.
Language:
English ...
Source: Merck.com - Research and Development News - September 23, 2013 Category: Pharmaceuticals Authors: hq_site_admin Tags: Research and Development News Corporate News Latest News Source Type: news
Merck and AstraZeneca Enter License Agreement for Investigational Oral WEE1 Kinase Inhibitor Therapy for Cancer
Dateline City:
WHITEHOUSE STATION, N.J. & LONDON
WHITEHOUSE STATION, N.J. & LONDON--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada,
and AstraZeneca (NYSE: AZN) today announced a worldwide licensing
agreement for Merck’s oral small molecule inhibitor of WEE1 kinase
(MK-1775). MK-1775 is currently being evaluated in Phase IIa clinical
studies in combination with standard-of-care therapies for the treatment
of patients with certain types of ovarian cancer.
Language:
...
Source: Merck.com - Research and Development News - September 11, 2013 Category: Pharmaceuticals Authors: hq_site_admin Tags: Research and Development News Corporate News Latest News Source Type: news
Merck Announces FDA Acceptance of New Drug Application for Investigational Fertility Treatment
Dateline City:
WHITEHOUSE STATION, N.J.
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced that the New Drug Application (NDA) for its
investigational fertility treatment, corifollitropin alfa, has been
accepted for standard review by the U.S. Food and Drug Administration
(FDA). Merck is seeking FDA approval of corifollitropin alfa for
Controlled Ovarian Stimulation (COS) in women participating in assisted
reproductive technology.
Language:...
Source: Merck.com - Research and Development News - September 9, 2013 Category: Pharmaceuticals Authors: hq_site_admin Tags: Research and Development News Corporate News Latest News Source Type: news
Merck Statement Regarding CHMP Review of Incretin-Based Therapies for Type 2 Diabetes, Including Sitagliptin
Dateline City:
WHITEHOUSE STATION, N.J.
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck, known as MSD outside the United States and Canada, issued the
following statement regarding the conclusion of the European Medicines
Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP)
review of GLP-1, or incretin-based, therapies, including sitagliptin.
Language:
English
Contact:
MerckMedia...
Source: Merck.com - Research and Development News - July 26, 2013 Category: Pharmaceuticals Authors: hq_site_admin Tags: Research and Development News Corporate News Latest News Source Type: news
Merck Announces FDA Acceptance of New Drug Application for Vorapaxar, Investigational Anti-Thrombotic Medicine
Dateline City:
WHITEHOUSE STATION, N.J.
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced that the New Drug Application (NDA) for its
investigational anti-thrombotic medicine, vorapaxar, has been accepted
for standard review by the U.S. Food and Drug Administration (FDA).
Merck is seeking FDA approval of vorapaxar for the secondary prevention
of cardiovascular events in patients with a history of heart attack and
no history of stroke or transie...
Source: Merck.com - Research and Development News - July 24, 2013 Category: Pharmaceuticals Authors: hq_site_admin Tags: Research and Development News Corporate News Latest News Source Type: news
Merck Statement on FDA Advisory Committee Meeting About Sugammadex Sodium Injection
Dateline City:
WHITEHOUSE STATION, N.J.
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada,
confirmed today that the U.S. Food and Drug Administration (FDA) has
cancelled Thursday’s discussion of sugammadex at the Anesthetic and
Analgesic Drug Products Advisory Committee (AADPAC). Sugammadex sodium
injection is Merck’s investigational medicine for the reversal of
neuromuscular blockade (NMB) induced by rocuronium or vecuronium.
Language:
...
Source: Merck.com - Research and Development News - July 16, 2013 Category: Pharmaceuticals Authors: hq_site_admin Tags: Research and Development News Corporate News Latest News Source Type: news
Merck Presents Findings from Phase 1b Study of Investigational BACE Inhibitor, MK-8931, in Patients with Alzheimer’s Disease
Dateline City:
WHITEHOUSE STATION, N.J.
Merck, known as MSD outside the United States and Canada, today announced the presentation of results from a Phase Ib study showing a dose-dependent decrease in β amyloid levels in cerebral spinal fluid (CSF) following administration of MK-8931, Merck’s investigational oral β-site amyloid precursor protein cleaving enzyme (BACE1 or β secretase) inhibitor, in patients with mild to moderate Alzheimer’s disease (AD). In the study, β amyloid levels were analyzed as a measure of BACE activity.
Language:
...
Source: Merck.com - Research and Development News - July 14, 2013 Category: Pharmaceuticals Authors: Maria.tortoreto at merck.com Tags: Alzheimer ' s disease BACE Darryle Schoepp Merck MK-8931 MRK MRL MSD Research and Development News Corporate News Latest News Source Type: news
Merck Receives Complete Response Letter for Suvorexant, Merck’s Investigational Medicine for Insomnia
Dateline City:
WHITEHOUSE STATION, N.J.
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada,
announced today that the company has received a Complete Response Letter
from the U.S. Food and Drug Administration (FDA) regarding the New Drug
Application for suvorexant, Merck’s investigational medicine for the
treatment of insomnia.
In the Complete Response Letter, the FDA advised Merck that:
Language:
Englis...
Source: Merck.com - Research and Development News - July 1, 2013 Category: Pharmaceuticals Authors: hq_site_admin Tags: Research and Development News Corporate News Latest News Source Type: news
Merck Announces Presentation of Interim Data from Study Evaluating Lambrolizumab, an Investigational Anti-PD-1 Antibody, in Patients with Advanced Melanoma at ASCO 2013
Dateline City:
WHITEHOUSE STATION, N.J.
-Merck Expands Lambrolizumab Clinical Development Program-
-Study Published Online in the New England Journal of Medicine-
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada,
today announced the presentation of preliminary results from an ongoing
Phase IB expansion study evaluating the safety and efficacy of
lambrolizumab (MK-3475), Merck’s investigational ant...
Source: Merck.com - Research and Development News - June 2, 2013 Category: Pharmaceuticals Authors: hq_site_admin Tags: Research and Development News Corporate News Latest News Source Type: news
Merck Provides Update on Phase III Clinical Program for Preladenant, the Company’s Investigational Parkinson’s Disease Medicine
Dateline City:
WHITEHOUSE STATION, N.J.
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada,
today provided an update on the clinical program for preladenant,
Merck’s investigational adenosine A2A receptor antagonist for
the treatment of Parkinson’s disease (PD). An initial review of data
from three separate Phase III trials did not provide evidence of
efficacy for preladenant compared with placebo.
Language:
E...
Source: Merck.com - Research and Development News - May 23, 2013 Category: Pharmaceuticals Authors: hq_site_admin Tags: Research and Development News Corporate News Latest News Source Type: news
Merck Statement on FDA Advisory Committee Meeting for Suvorexant
Dateline City:
WHITEHOUSE STATION, N.J.
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada,
today provided the following statement after the conclusion of the
Peripheral and Central Nervous System Drugs Advisory Committee meeting
of the U.S. Food and Drug Administration (FDA) about suvorexant, Merck’s
investigational medicine to treat insomnia.
Language:
English
Contact HTML:
...
Source: Merck.com - Research and Development News - May 22, 2013 Category: Pharmaceuticals Authors: hq_site_admin Tags: Research and Development News Corporate News Latest News Source Type: news
